Compare PLNT & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLNT | ABVX |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 9.0B |
| IPO Year | 2015 | N/A |
| Metric | PLNT | ABVX |
|---|---|---|
| Price | $105.85 | $114.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $118.42 | $118.33 |
| AVG Volume (30 Days) | 1.3M | ★ 1.9M |
| Earning Date | 02-24-2026 | 08-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.23 | N/A |
| EPS | ★ 2.44 | N/A |
| Revenue | ★ $1,202,700,000.00 | $6,231,374.00 |
| Revenue This Year | $21.43 | $6.80 |
| Revenue Next Year | $11.05 | N/A |
| P/E Ratio | $42.77 | ★ N/A |
| Revenue Growth | ★ 14.63 | N/A |
| 52 Week Low | $87.72 | $4.77 |
| 52 Week High | $114.47 | $148.83 |
| Indicator | PLNT | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 43.99 | 43.25 |
| Support Level | $103.49 | $116.20 |
| Resistance Level | $110.53 | $129.56 |
| Average True Range (ATR) | 2.44 | 7.87 |
| MACD | -0.84 | -2.47 |
| Stochastic Oscillator | 36.59 | 15.05 |
Planet Fitness Inc is a franchisor and operator of fitness centers in the United States. The company's reportable segments are Franchise, Corporate-owned stores, and Equipment. Franchise segment includes operations related to its franchising business in the United States, Puerto Rico, Canada, Panama, Mexico and Australia, Corporate-owned stores segment includes operations with respect to all corporate-owned stores throughout the United States and Canada, and The Equipment segment includes the sale of equipment to franchisee-owned stores in the U.S. The firm generates a majority of its revenue from the Corporate-owned stores segment.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.